美国Fluxion
美国Fluxion成立于2005年.
Fluxion Biosciences was formed in 2005 to address critical needs for cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.

Customer Focused
Fluxion's goal is to create innovative solutions for its customers which offer superior performance, simplified workflows and cost savings over conventional assay techniques. Fluxion's customers include:

Biotech and pharmaceutical companies
Leading academic institutions
Government research organizations

Product Development Strategy
Fluxion works closely with its customers and collaborators to develop new products and applications. The company's first two products, BioFlux and IonFlux, were the result of extensive product development and testing both internally and with leading academic and biopharmaceutical institutions.

In 2008, BioFlux 200 was the recipient of the R&D 100 Award given by R&D Magazine to the top 100 new technologies of the year.

Advanced Research and Development
In addition to its core product lines, Fluxion is also engaged in cutting-edge research to produce the next generation of breakthrough technologies. Fluxion has been awarded several research grants from the National Institutes of Health to develop platforms for critical disease research areas.

Leadership
Fluxion is led by an experienced team of professionals from the bioanalytical tool industry. The Board of Directors comprises senior executives and investors representing some of the leading biotech and technology companies in the industry.

BioFlux system for live cell analysis under shear flow
IonFlux system for automated patch clamping